WARSAW, Ind.--(BUSINESS WIRE)--Biomet, Inc., a global leader in the manufacture of orthopedic and biotechnology products, announced today that enrollment in the Company’s SternaLock® Blu clinical trial has begun. The SternaLock® Blu clinical trial is a prospective, randomized, controlled, multicenter trial that will compare patients whose sternum is closed with conventional wire cerclage to patients whose sternum is closed with Biomet’s SternaLock® Blu Primary Closure System to evaluate sternal bone healing following a full median sternotomy. Additional outcomes on post-operative pain and analgesic usage, patient function and quality of life, and complications will also be collected. The study will also compare the economic costs between the two groups.
